Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Marie Helleberg(Rigshospitalet), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Kasper Sommerlund Moestrup(Copenhagen University Hospital), Carsten Utoft Niemann(University of Copenhagen), Clifford Lane(National Institutes of Health), Anne‐Mette Lebech(Copenhagen University Hospital), Ole Kirk(University of Copenhagen)
The Journal of Infectious Diseases
July 17, 2020
10.1093/infdis/jiaa446
Cited by 152

Related Papers

Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987